[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-374059-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-374059-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","anti-il-6r-ab-tocilizumab-to-treat-paraneoplastic-inflammatory-syndrome-of-solid-cancers","Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers","","Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare, severe complication often driven by systemic interleukin-6 (IL-6) production by cancer cells. This single-center analysis evaluated the efficacy of tocilizumab, an anti-IL-6 receptor antibody, in 35 patients with severe PIS and solid tumors treated between 2019 and 2024. Tocilizumab rapidly resolved paraneoplastic fever in all patients and reduced key inflammatory biomarkers, while many experienced relapse within 4–6 weeks after a single injection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/anti-il-6r-ab-tocilizumab-to-treat-paraneoplastic-inflammatory-syndrome-of-solid-cancers/374059/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/anti-il-6r-ab-tocilizumab-to-treat-paraneoplastic-inflammatory-syndrome-of-solid-cancers/374059.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main cause of paraneoplastic inflammatory syndrome (PIS) described in the document?","Question",{"text":63,"@type":64},"PIS is mediated by systemic overproduction of IL-6 by cancer cells, leading to fever and biological inflammation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was tocilizumab used in this study?",{"text":68,"@type":64},"All 35 patients with solid cancers and PIS treated with tocilizumab between 2019 and 2024 were analyzed in a single-center study, with clinical and biological effects reported.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment effect did tocilizumab show on inflammatory symptoms and biomarkers?",{"text":72,"@type":64},"All patients experienced resolution of paraneoplastic fever, and decreases in CRP, PMN, and platelet counts were observed in the vast majority, with some patients showing relapse 4–6 weeks after a single injection.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},374059,1790471406,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL ARTICLE  \nAnti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers  \nJ.-Y. Blay1, 2􀀁, M. Brahmi1, 2, A. Dufresne1, 2, A. Swalduz1, 2, V. Avrillon1, S. Assaad1, C. Decroisette1, B. Mastroianni1, M. Dupont1, F. Bourbotte-Salmon1, I. Ray-Coquard1, 2, P. Meeus1, A. Dutour2, M. Castets2, M. Perol1 & P. Heudel1  \n1Department of Medicine and DRCI, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon; 2Centre de Recherche en Cancérologie de Lyon, Equipe 4, Lyon, France  \nAvailable online xxx  \nBackground: Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare but severe condition often caused by the systemic production of interleukin 6 (IL-6) by cancer cells. We report on the efficacy of tocilizumab, an anti-IL-6 receptor antibody, in 35 patients with severe PIS.  \nPatients and methods: All 35 patients with solid cancers (sarcomas, lung carcinoma, and breast carcinoma) diagnosed with a PIS from 2019 to 2024 treated with tocilizumab were analyzed in this single-center study (health authorities’approval R201-004-478) . Patients’ characteristics and clinical and biological effects of tocilizumab administration arepresented.  \nResults: Thirty-five (97%) patients had paraneoplastic fever. The median performance status (PS) was 2 (range 1-4) . Forty percent of patients had lost 10% of body weight. All had increased serum C-reactive protein (CRP) levels (median 212 mg/l), and 74% and 48% had increased polymorphonuclear leukocyte (PMN) and platelet counts, respectively. Ninety-four percent had inflammatory anemia. Tocilizumab was given once in 23 (66%) patients and more than once in 12 patients. All patients experienced resolution of paraneoplastic fever, and 11 (31%) had improved PS. CRP, PMN, and platelet count decreases were observed in 100%, 85%, and 94% of patients, respectively. Seventy-seven percent of patients had increased hemoglobin levels. CRP and inflammatory symptoms often relapsed 4-6 weeks after tocilizumab in patients receiving only one injection.  \nConclusions: Tocilizumab is an efficient treatment for severe PIS providing significant improvement in clinical symptoms and biological abnormalities.  \nKey words: IL-6, paraneoplastic inflammatory syndrome, tocilizumab, sarcoma, lung cancer  \nINTRODUCTION  \nParaneoplastic inflammatory syndrome (PIS) is a rare but severe condition associated with solid cancers, with negative prognostic implications.1-15 PIS is diagnosed after the exclusion of infection and other causes of inflammation. It is mediated by the release of cytokines, hormones, or other immune-modulating factors by cancer cells.1 Clinical symptoms include fever, fatigue, night sweats, decreased performance status (PS), weight loss, and cachexia. Biological symptoms include C-reactive protein (CRP) increase, neutrophilia, with occasional leukemoid reactions, thrombocytosis, and inflammatory anemia.1-15  \nThe overproduction of interleukin 6 (IL-6) by solid cancer cells has been reported to be involved in the pathogenesis  \n*Correspondence to: Prof. Jean-Yves Blay, Department of Medicine, Centre Léon Bérard, 28, Rue Laennec, 69008 Lyon, France. Tel: þ33478785126  \nE-mail: [jean-yves.blay@lyon.unicancer.fr](jean-yves.blay@lyon.unicancer.fr) (J.-Y. Blay).  \n2059-7029/© 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nof these systemic clinical and biological symptoms.4,6, 15-19 IL-6 is a multifunctional cytokine that plays a pivotal role in immune responses, inflammation, and hematopoiesis.18-21 Under normal physiological conditions, IL-6 is involved in the acute-phase response to infections and tissue injuries, facilitating the activation and differentiation of B and T cells, as well as the production of acute-phase proteins by the liver. However, in the cont","cbCaisXOmiUesHrJ","https://ap.wps.com/l/cbCaisXOmiUesHrJ","pdf",707494,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the main cause of paraneoplastic inflammatory syndrome (PIS) described in the document?\",\"answer\":\"PIS is mediated by systemic overproduction of IL-6 by cancer cells, leading to fever and biological inflammation.\"},{\"question\":\"How was tocilizumab used in this study?\",\"answer\":\"All 35 patients with solid cancers and PIS treated with tocilizumab between 2019 and 2024 were analyzed in a single-center study, with clinical and biological effects reported.\"},{\"question\":\"What treatment effect did tocilizumab show on inflammatory symptoms and biomarkers?\",\"answer\":\"All patients experienced resolution of paraneoplastic fever, and decreases in CRP, PMN, and platelet counts were observed in the vast majority, with some patients showing relapse 4–6 weeks after a single injection.\"}]","Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers | PDF",1790201080]